CFRX ContraFect Corporation

5.45
+0.06  (+1%)
Previous Close 5.39
Open 4.73
Price To Book 9.73
Market Cap 83,559,629
Shares 15,332,042
Volume 1,944,121
Short Ratio
Av. Daily Volume 172,484
Stock charts supplied by TradingView

NewsSee all news

  1. ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

    YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of

  2. ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

    YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of

  3. ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update

    YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  4. ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book

    YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  5. ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim's Infectious Disease Virtual Conference

    YONKERS, N.Y. , April 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 initiation of dosing announced January 10, 2020.
CF-301 exebacase
Serious infections caused byStaph aureus including MRSA

Latest News

  1. ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

    YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of

  2. ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

    YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of

  3. ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update

    YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  4. ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book

    YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  5. ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim's Infectious Disease Virtual Conference

    YONKERS, N.Y. , April 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins

  6. ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference

    YONKERS, N.Y., March 30, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins

  7. ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    YONKERS, N.Y., March 18, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins

  8. ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development

    YONKERS, N.Y., March 04, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins

  9. ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis

    YONKERS, N.Y., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  10. ContraFect Announces One-for-Ten Reverse Stock Split

    YONKERS, N.Y., Feb. 04, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  11. ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology

    YONKERS, N.Y., Feb. 03, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  12. ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    YONKERS, New York, Jan. 27, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including Lysins

  13. ContraFect to Present at 2020 ASM Biothreats

    YONKERS, N.Y., Jan. 22, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  14. ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections

    YONKERS, N.Y., Jan. 13, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  15. ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

    YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  16. ContraFect to Present at Biotech Showcase 2020

    YONKERS, N.Y., Jan. 06, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  17. ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

    YONKERS, N.Y., Dec. 20, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  18. ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

    YONKERS, N.Y., Dec. 18, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  19. ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock

    YONKERS, N.Y., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of

  20. NexImmune Appoints Sol Barer as Chairman of the Board of Directors

    GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology

  21. ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer

    YONKERS, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of

  22. ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

    YONKERS, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of

  23. ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference

    YONKERS, N.Y., Nov. 29, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  24. ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update

    YONKERS, N.Y., Nov. 12, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  25. ContraFect to Present at the World Anti-Microbial Resistance Congress 2019

    YONKERS, N.Y., Nov. 05, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  26. ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

    Primary Endpoint of Clinical Response at Day 14 in Patients with Methicillin-Resistant Staph aureus (MRSA) Bacteremia, including Right-Sided Endocarditis Study Initiation Planned by Year-End 2019 Conference Call

  27. ContraFect to Host Development Update Call and Webcast on October 2, 2019

    YONKERS, N.Y., Oct. 01, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and

  28. ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019

    YONKERS, N.Y., Sept. 26, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins

  29. ContraFect to Present at the 2019 Janney Healthcare Conference

    YONKERS, New York, Sept. 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including

  30. ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

    YONKERS, N.Y., Aug. 28, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and